Advertisement

Topics

MGC Diagnostics Corporation Announces Annual Meeting of Shareholders and Fiscal 2016 Year-end Letter to Shareholders

12:14 EDT 20 Mar 2017 | PR Newswire

SAINT PAUL, Minn., March 20, 2017 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), a global medical technology company, today announced details for its upcoming Annual Meeting of Shareholders and its fiscal 2016 year-end letter to shareholders.

Annual Meeting of ShareholdersMGC Diagnostics Corporation's 2017 Annual Meeting of Shareholders will be on Wednesday, March 22, 2017, beginning at 3:30 P.M. CDT. The meeting will be held at MGC's offices located at 350 Oak Grove Parkway, Saint Paul, Minnesota 555127.

Year-end Letter to Shareholders Please click the link to view our year-end letter to shareholders which can be found in the Business Overview 2016:http://mgcdiagnostics.com/investor-relations/annual-reports.

About MGC DiagnosticsMGC Diagnostics Corporation (NASDAQ: MGCD), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company, through its Medical Graphics Corporation and Medisoft SA subsidiaries, develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and, in the United States, France and Belgium, primarily through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward Looking StatementsFrom time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws. These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors, see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2016, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.

Contacts

Company

Investors

Todd M. Austin

Joe Dorame, Robert Blum, Joe Diaz

MGC Diagnostics Corporation

Lytham Partners, LLC

Chief Executive Officer

(602) 889-9700

(651) 484-4874

mgcd@lythampartners.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mgc-diagnostics-corporation-announces-annual-meeting-of-shareholders-and-fiscal-2016-year-end-letter-to-shareholders-300426442.html

SOURCE MGC Diagnostics Corporation

NEXT ARTICLE

More From BioPortfolio on "MGC Diagnostics Corporation Announces Annual Meeting of Shareholders and Fiscal 2016 Year-end Letter to Shareholders"

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...